|
 |
What's New
Notices for Pharmacists
Tuesday, November 14, 2006
Hoffmann-La Roche Limited, following discussions with Health Canada, would like to inform health care professionals of new safety information regarding the use of RITUXAN®. Reports of abdominal pain, bowel obstruction, and perforation, in some cases leading to death, have been observed in patients receiving the drug for the treatment of B-cell non-Hodgkin's Lymphoma (NHL) and Rheumatoid Arthritis (RA). More...
Drug Warnings for Consumers
Tuesday, November 14, 2006
Health Canada wishes to advise consumers that there have been reports of bowel obstruction and perforation with the drug RITUXAN®. RITUXAN® has been authorized for use in Canada since 2000 and is used to treat non-Hodgkin's lymphoma (a cancer of the lymph nodes) and rheumatoid arthritis. More...
Drug Schedules Notice Board
Wednesday, October 25, 2006
The next meeting of the National Drug Scheduling Advisory Committee (NDSAC) is scheduled for December 3-4, 2006. More...
Announcements
Thursday, September 21, 2006
A collaborative of eight leading Canadian pharmacy organizations is surveying pharmacists and pharmacy technicians from across Canada to gain a better understanding of the current and potential role of pharmacy technicians. More...
|
|
|
| |
